Jefferies Downgrades Mereo BioPharma Group to Hold, Lowers Price Target to $0.5
Benzinga Newsdesk 10 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Jefferies analyst Maury Raycroft downgrades Mereo BioPharma Group (NASDAQ:MREO) from Buy to Hold and lowers the price target from $7 to $0.5.
Jefferies analyst Maury Raycroft downgrades Mereo BioPharma Group (NASDAQ:MREO) from Buy to Hold and lowers the price target from $7 to $0.5.